期刊
DIABETES OBESITY & METABOLISM
卷 25, 期 5, 页码 1372-1384出版社
WILEY
DOI: 10.1111/dom.14989
关键词
antidiabetic drug; type 2 diabetes; cardiovascular disease; diabetes complications
This study used the diabetes staging system (DSS) to assess the association between disease stage and mortality rates in type 2 diabetes cardiovascular outcome trials, and found that higher DSS stage was associated with increased rates of all-cause mortality and cardiovascular death.
Aims To apply the diabetes staging system (DSS), a novel disease staging system similar to what is used in oncology but designed to improve diabetes management, to three large type 2 diabetes (T2D) cardiovascular (CV) outcome trials to assess whether increasing DSS stage was associated with higher rates of all-cause mortality (ACM) and/or CV death.Materials and Methods The DSS uses discrete CV events (none to >= 3: Stage 1 to 4), end-stage kidney disease (Stage 5) and microvascular complications (none to 3: A to D) to determine disease stage in individuals with T2D. The DSS stage for patients from the CAROLINA, EMPA-REG OUTCOME and CARMELINA trials was determined. Incidence rates for ACM/CV death were calculated across DSS stages and Cox regression analyses were performed.Results The risk of ACM or CV death increased with increasing DSS (Stage 1 to 5; P for trend < 0.0001) in all trials. In CAROLINA, the risk of ACM and CV death increased with increasing number of microvascular complications (A to D; both P for trend < 0.0001), similar in CARMELINA (P for trend = 0.0020 and 0.0005, respectively). In EMPA-REG OUTCOME, having all three microvascular complications (Stage D), versus none, increased the risk of ACM and CV death (P = 0.0015 and 0.0010, respectively).Conclusions Applying the DSS across T2D clinical trial populations with different CV risk revealed a significantly increased risk of ACM and CV death with higher DSS stage. The DSS may merit assessment in other T2D populations and evaluation of the impact of additional outcomes, such as heart failure, could also be worthwhile.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据